Newsroom


22.01.2018
Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication &n...

21.11.2017
Octapharma donates 30.5 million international units of its medicine Nuwiq® to treat people with haemophilia in developing countries

Lachen, Switzerland, November 21st, 2017: Octapharma is pleased to announce the completion of a ch...

Career

Octapharma’s success is the result of the combined contribution of all employees, what we call “the human factor”. To embark on a challenging and rewarding career in an innovative biopharmaceutical organization, explore our global opportunities